B. De la Puente (Majadahonda, Spain)
Hospital Universitario Puerta de Hierro - (INSALUD)Author Of 1 Presentation
- B. Nunez Garcia (Majadahonda, Spain)
- J. Sanchez (Majadahonda, Spain)
- M. Blanco Clemente (Majadahonda, Spain)
- M. Mendez Garcia (Majadahonda, Spain)
- M. Vega (Majadahonda, Spain)
- S. Carmona (Majadahonda, Spain)
- B. De la Puente (Majadahonda, Spain)
- A. Morito Aguilar (Majadahonda, Spain)
- M. Provencio Pulla (Majadahonda, Ma, Spain)
- B. Cantos Sanchez De Ibarguen (Majadahonda, Spain)
174P - Breast screening at young age. A real need?
Abstract
Background
Screening mammography are stablished between the age of 50-69 years in most countries with a few exceptions in those patients with a higher risk (BRCA, Family background…). Breast cancer in patients under 45 is about 15% of all new diagnosis. The clinical impact of treatment is often significant in this particular vulnerable population.
Methods
A retrospective observational study of young breast cancer patients (YBCP ≤45 years old) diagnosed between 2009-2019 in HUPHM was carried out. The main objective was to explore difference between asymptomatic patients (screening) versus symptomatic patients (lump, swelling, pain…). Epidemiological, clinical, pathologic and treatment information was collected.
Results
We analyzed 590 young patients (≤ 45 years old) with a new diagnosis of in situ or infiltrating breast cancer. Results are summarized in the table below.
Asymptomatic Symptomatic univariate analysis, p N (%) 162 (27%) 428 (73%) Median age/range 41,9 (26-45) 41,2 (28-45) Stage 0 (in situ) 20% 5% p=0.001 Stage I 46% 30% p=0.001 Stage II 25% 40% p=0.001 Stage III 6% 20% p=0.001 Stage IV 3% 5% p=0.01 Family background 40% 32% p=0.091 BRCA 1/2 8% 5% p=0.14 Lymph node positive 24% 45% p=0.0001 Mastectomy/Breast conservative 64%/36% 72%/28% p=0.1 Neoadyuvant CT 13% 30% p=0.0001 CT neo or adyuvant 54% 79% p=0.0001 Radiotherapy 31% 54% p=0.0001 Relapse 11% 17% p=0.02
Conclusions
Most women under 45 years are diagnosed with breast cancer due to symptoms, since they are excluded from screening programs. No differences were found in family background between the two groups. Women who are screened are diagnosed with a statistically significantly lower stage, less lymph node involvement, receive less chemotherapy, less radiotherapy, and have fewer relapses. Screening programs in young patients could avoid some of the treatments and related late side effects.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.